Comparative Pharmacology
Head-to-head clinical analysis: PENICILLIN G POTASSIUM versus SPECTROBID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PENICILLIN G POTASSIUM versus SPECTROBID.
PENICILLIN G POTASSIUM vs SPECTROBID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bactericidal: inhibits transpeptidases (penicillin-binding proteins) involved in bacterial cell wall synthesis, leading to cell lysis.
Spectrobird (bacampicillin) is a prodrug of ampicillin, a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
1-4 million units IV every 4-6 hours; maximum 24 million units/day
400 mg orally twice daily or 200 mg orally four times daily for 10-14 days. For acute exacerbations of chronic bronchitis: 400 mg orally twice daily for 10 days.
None Documented
None Documented
0.5-1 hour in normal renal function; prolonged to 3-10 hours in anuria/end-stage renal disease.
Terminal elimination half-life: 1.5-2 hours in normal renal function; prolonged to 6-10 hours in severe renal impairment (CrCl <10 mL/min).
Renal (60-90% as unchanged drug via tubular secretion and glomerular filtration); biliary (minor, <10%); fecal (minimal, <5%).
Renal: ~75-85% unchanged drug; fecal/biliary: ~15-25% as metabolites and unchanged drug.
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic